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1. Introduction 
Glioblastoma is the most common form of primary brain tumor. The incidence of this tumor 
is fairly low, with 2-3 cases per 100,000 people in Europe and North America 1. It is one of 
the most aggressive forms of cancer 2. Without treatment, the median survival is 
approximately 3 months 3. The current standard of treatment involves maximal surgical 
resection followed by concurrent radiation therapy and chemotherapy with the DNA 
alkylating agent, temozolomide 4. With this regimen, the median survival is approximately 
14 months. For nearly all affected, the treatments available remain palliative. 
The best available evidence suggests that glioblastomas originate from cells that give rise to glial 
cells5, 6. These glial derived tumors are graded by the World Health Organization (WHO) into 4 
categories, termed WHO grade 1 to grade 4. The higher grade denotes histologic features of 
increased malignancy. WHO 4 glioma is essentially synonymous with glioblastoma7. 
Studies carried out over the past three decades suggest that glioblastomas, like other 
cancers, arise secondary to the accumulation of genetic alterations. These alterations can 
take the form of epigenetic modifications, point mutations, translocations, amplifications or 
deletions and modify gene function in ways that deregulate cellular signaling pathways 
leading to the cancer phenotype 8. The exact number and nature of genetic alterations and 
deregulated signaling pathways required for tumorigenesis remains an issue of debate9, 
although it is now clear that CNS carcinogenesis requires multiple disruptions to the normal 
cellular circuitry. The genetic alteration results in either activation or inactivation of specific 
gene functions that contribute to the process of carcinogenesis 9. Genes, that when activated, 
contribute to the carcinogenesis are generally termed proto-oncogenes. The mutated forms 
of these genes are referred to as oncogenes. Genes, that when inactivated, contribute to the 
carcinogenesis are generally termed tumor suppressor genes. 
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Despite some progress in the clinical management of glioblastoma, prognosis of patients 
suffering from this deadly tumor remains dismal, and design of new and more effective 
therapies for glioblastoma is highly desirable. Arguably the most promising route to 
discoveries of innovative treatment strategies is to obtain better mechanistic insights into 
glioblastoma pathogenesis and biology. Indeed, recent research in this area of experimental 
and clinical oncology has identified the key signaling pathways, critical regulatory nodes, 
genes and their protein products, as well as their mutual cross-talks, thereby providing a 
solid molecular basis for selection of candidate therapeutic targets and drug discovery 
programs. These lines of investigation complement the recent efforts to sequence entire 
genomes of a growing number of human tumors including glioblastoma, formulation of 
new concepts and principles in tumor cell biology, and potential exploitation of these major 
advances for personalized disease management in oncology. Collectively, such efforts have 
begun to provide exciting leads to conceptual framework that afford innovative therapeutic 
strategies. This review will aim to review these critical concepts and their relevance for 
glioblastoma therapeutic development. 
2. Concept 1: Glioblastoma subtypes 
There is an old adage that cancer is a hundred diseases masquerading in one. While this 
adage is based on clinical and pathologic observations, systemic genomic characterization of 
a large number of glioblastoma specimens (TCGA) confirms the notion that subtypes with 
distinct pathologic molecular events and therapeutic response. 
The Cancer Genome Atlas (TCGA) is a major NIH initiative involving institutions spanning 
the continental U.S. with the goal of tumor specimen collection and molecular 
characterization 10. Glioblastoma was one of the first tumor types characterized in this effort. 
This vast wealth of data is unprecedented, and despite the enormous challenge to process 
and analyze this incoming information, correlations of such emerging ‘genetic and 
expression profiles’ or ‘tumor landscapes’ with tumor biology and clinico-pathological 
features of the patients including therapeutic responses are beginning to impact oncology.  
This profiling approach 11 has led to the understanding that glioblastoma is but an umbrella 
term that encapsulates subtypes characterized by distinct molecular properties. Based on 
global transcript profiling, glioblastoma can be divided into three to four distinct subtypes 
11, 12. Interestingly, each subtype harbor distinct genetic aberrations 12 and proteomic profiles 
13. The recognition that glioblastoma consists of subtypes varying in molecular circuitry and 
biologic behavior suggests that no therapy can be universally efficacious. The major 
importance of this concept of heterogeneity is that meaningful therapeutic gain can only be 
attained by customizing the therapy to the underlying molecular circuit. 
One subtype (termed classical by the TCGA and proliferative by Philips et al) is 
characterized by frequent amplification or mutations in the Epidermal Growth Factor 
Receptor (EGFR) gene 10, 11. In contrast, in another subtype, termed proneural by both 
groups, harbored frequent mutations in p53, Platelet Derived Growth Factor Receptor A 
(PDGFRA), and Isocitrate Dehydrogenase 1 (IDH1) 12. A third type, termed mesenchymal by 
both groups, is characterized by frequent mutations in the Neurofibromatosis type 1 gene 
(NF-1). Of note, these subtypes differ in their clinical responses to therapy. Patients afflicted 
with the classical (proliferative) or mesenchymal subtypes benefit from radiation and 
temozolomide treatment 12. Such benefit was not observed in patients afflicted with the 
proneural subtype. 
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3. Concept 2: Oncogene addiction  
The term “oncogene addiction” was initially coined by Dr. Bernard Weinstein to describe 
the phenomenon that some tumors exhibit exquisite dependence on a single oncogenic 
protein (or pathway) for sustaining growth and proliferation 14. Such dependence has been 
convincingly demonstrated in both tissue culture and transgenic mice systems for oncogenic 
versions of MYC 15-17 and RAS 18. Application of this concept to the clinical setting has 
achieved variable success in various cancer types, including chronic myelogeneous 
leukemia (CML) harboring the BCR-ABL translocation, Erb2 over-expression breast cancer, 
and Non-Small Cell Lung Cancer harboring selected EGFR mutations 19, 20. A simplistic 
application of this concept in glioblastoma would involve identification of the critical 
“addicted” oncogene followed by the inhibition of such oncogene(s). Unfortunately, the 
actual biology of glioblastoma is far more complex. 
To understanding this complexity, a careful analysis of the fundamental notion of oncogenic 
addiction is needed. In some ways, the observation that tumors exhibit dependence on a 
particular oncogenic pathway at some point in its history is not surprising. However, taken 
in the context of the plethora of dynamic genetic changes that accumulated during cancer 
progression 21, it is somewhat anti-intuitive to suspect that any particular pathway would 
play a prominent role in maintaining cell viability. Moreover, inactivation of the normal 
counterpart of the addicted oncogenic protein is often tolerated in normal tissue. These 
observations suggest that the genetic circuitry of the cancer cell have been extensively re-
programmed to result in this “addicted” state 14.  
The molecular nature of this re-programming remains poorly understood. Several 
hypotheses have been put forward. One hypothesis involves the notion of “genetic 
streamlining”, where genetic instability in cancer cells is thought to mutationally or 
epigenetically inactivate certain signaling pathways that are operational in a normal cell but 
not required for growth in the cancer cell. In this “streamlined” state, the tumor cell becomes 
hyper-dependent on the oncogene driven processes 22. A more generalized form of this 
explanation involved the notion of synthetic lethality. Two genes are considered 
synthetically lethal if cells remain viable with inactivation of either gene. Simultaneous 
inactivation of both genes, on the other hand, results in cell death 23. It is thought that the 
cancer cells have accumulated mutations that are synthetically lethal with the absence of 
critical oncogenes. The main difference between this hypothesis and the “streamline” 
hypothesis is that the mutation in the former can result in a gain or loss of function, whereas 
the later specifically proposes a loss of function. A third hypothesis suggests that oncogenes 
reprogrammed the tumor cell by both pro-survival and pro-apoptotic signaling 22. With 
acute inactivation, the pro-survival signaling decayed faster than the pro-apoptotic 
signaling, resulting in tumor death. 
The main reason for revisiting the framework of oncogene addiction is that mechanism by 
which the cells can evolve to avoid such addiction. For instance, in the context of synthetic 
lethality, EGFR inhibition may be cytotoxic to glioblastoma cells only in the appropriate 
genetic context. Indeed, therapeutic effects of EGFR inhibition were observed only in 
patients with tumors harboring an oncogenic form of EGFR and an intact PTEN tumor 
suppressor gene 24. To complicate the matter, recent studies demonstrate that glioblastomas 
harbor activation of multiple oncogenic Receptor Tyrosine Kinases (RTKs), such that 
inactivation of any single oncogene merely diverts signaling through other active oncogenes 
25. In these contexts, it is evident that meaningful therapy will require simultaneous 
inhibition of multiple oncogenes or identification of the fitting genetic context. 
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4. Concept 3: Non-oncogene addiction 
Emerging literature suggests an alternative strategy to the multi-target approach. These 
studies reveal that oncogene activation introduces secondary physiologic changes that stress 
cellular capacity for survival. Consequently, tumor cells become hyper-dependent on 
processes required to compensate for these stressful conditions 26, 27. This phenomenon is 
termed “non-oncogene addiction” since the compensatory processes required for tumor 
survival do not directly contribute to the cancer formation. In other words, even genes that are 
not themselves targeted by tumorigenic mutations may well become essential for the tumor to 
survive the stressful environment and fuel the demanding process of tumor progression. 
Consequently, interference with the function of such genes can be rate-limiting to the 
particular mechanism in the tumor, but not as much in the normal counterpart cells. 
Importantly, such adaptively essential genes that underlie the ‘non-oncogene addiction’ 26, 27 of 
cancer cells can be therapeutically targeted if suitable drugs or other approaches are available.  
There are several examples of such critical non-oncogenic pro-survival functions required 
for maintenance of the tumorigenic state in glioblastoma. EGFR is a critical proto-oncogene 
in glioblastoma pathogenesis 10, 28. Our laboratory has demonstrated that EGFR 
hyperactivation results in increased accumulation of reactive oxygen species (ROS), which 
in turn cause cytotoxic DNA damage. To compensate for the deleterious effect of ROS, 
EGFR hyperactive glioblastomas exhibit increased reliance on DNA repair process that 
repair ROS related DNA damage 29. Selective targeting of EGFR hyperactive glioblastomas 
can, thus, be achieved by inhibition of these repair process. Other groups have 
demonstrated that EGFR hyperactivation in glioblastoma cell lines heightens requirement 
for lipogenesis 30, 31. Other examples of such critical non-oncogenic pro-survival functions 
required for maintenance of the tumorigenic state include dependency on mechanism for 
compensating mitotic and proteotoxic stress and interplay with the tumor 
microenvironment including the immune system 26. While illustrative examples of strategies 
based on these “non-oncogene” addiction paradigms have been established in other cancers, 
the pertinence to glioblastoma awaits rigorous interrogation. 
The principle of non-oncogene addiction suggests that there is a wider spectrum of 
therapeutic options than afforded under the paradigm of “oncogene addiction”. In many 
cases, compensatory processes involved in “non-oncogene addiction” are the same as those 
that basic scientists have studied for years (for instance, DNA repair). Mechanistic 
investigations into these biologic processes by the basic scientists have yielded a rich 
database of inhibitors. Thus, identifying gene functions that compensate for oncogene 
induced cellular stress should afford opportunities to tap into this rich database and expand 
the denominator of drugs available for combinatorial therapy. Identifying genes that are 
synthetically lethal with oncogenes constitute an attractive means to this end. 
It is important to note that effects of therapies designed based on the principles of 
“oncogene addiction” and of “non-oncogene addiction” are inherently antagonistic. For 
instance, EGFR inhibition leads to a reduction of ROS, obviating the need for DNA repair 29. 
In this context, combination of DNA repair inhibition and EGFR inhibition would not be 
desirable. Rational strategies for synthesizing the two therapeutic paradigms remains a 
major intellectual challenge. 
5. Concept 4: Tumor initiating cells  
Another advance that may profoundly change our thinking about solid tumors including 
glioblastoma involves the concept of tumor initiating cells. The experimental observation is 
www.intechopen.com
 
Key Principles in Glioblastoma Therapy 
 
57 
that within a total population of glioblastoma cells, there appears to be a small sub-
population of cells that are highly tumorigenic (hence the term “tumor initiating cells” or 
“TICs”) with tremendous capacity for self-renewal 32, 33. To the extent that glioblastoma 
tumor initiating cells share many common properties when compared to neural stem cells, it 
is proposed that the TICs originated from stem cells. While there are some data supporting 
this hypothesis 5, the universality of this hypothesis remain controversial. 
Protein markers to prospectively identify and isolate these putative TICs such as the 
transmembrane glycoprotein CD133 (prominin-1) in glioblastomas have been identified 5. 
However, the value of CD133 as a single marker of glioblastoma TICs remains controversial, 
partly because also CD133-negative glioblastoma cells could give rise to tumors in an 
intracranial mouse xenograft model 34-36. These uncertainties motivate an ongoing search for 
additional candidate TIC markers. Candidate cell surface molecules suggested in this 
context include the adhesion glycoprotein L1CAM 37, surface carbohydrate antigen CD15 
(SSEA-1) 38, surface marker A2B5 39, and integrin 6 40. Currently, there are no generally 
accepted cell surface markers for defining TIC. The definition of TICs remains a functional 
one as defined by the ability of a tumor cell to sustain self-renewal and initiate glioblastoma 
formation in immuno-compromised xenograft models.  
Arguably, the most important aspect of the concept of TICs is that this population appeared 
particularly resistant to conventional radiation and chemotherapy 32. In this context, TICs 
may be responsible for glioblastoma recurrence after conventional therapy. Given such 
properties, it is understandable that glioblastoma research has recently focused on 
identification and development of potential anti-TIC therapies. Two of these strategies, 
namely targeting the TICs as part of a vascular niche, and attempts to overcome their 
therapeutic resistance, will be discussed in the following sections on glioblastoma 
angiogenesis and the role of DNA damage response pathways, respectively. Here, we 
briefly consider strategies that are emerging as potentially fruitful approaches to treat 
glioblastoma through targeting TICs.  
The first strategy reflects the efforts to identify suitable cell surface markers to reliably 
identify glioblastoma TICs – with the hope of conjugating the corresponding antibody to 
cytotoxic compounds as therapeutic agents. The second strategy is based on observations 
that some TICs, like neural stem cells, can be induced into a differentiated state whereby the 
self-renewal properties are lost. Among the suggested agents to induce such TIC 
differentiation, the bone morphogenetic proteins (BMPs) appear promising 41. The third 
strategy involves modulating specific signaling pathways required for maintaining the TIC 
state. Pathways targeted include those mediated by EGFR, Wnt-beta catenin, STAT3, Sonic 
Hedgehog-Gli, and Notch pathways 42. To the extent that these pathways are also regulated 
by miRNAs such as miR-21 43, such miRNA constitute therapeutic targets in this strategy. 
Finally, normal neural stem cells have been shown to migrate toward and track TICs. Based 
on this principle, neural stem cells have been as delivery vehicles to increase local 
concentration of therapeutic agents in the vicinity of TICs 44.  
6. Summary 
In this chapter, we have discussed key principles underlying current development of 
glioblastoma therapeutics. Emphasis was placed on conceptual framework rather than 
specific drugs or targets. These frameworks should serve as the basis for translating 
fundamental biologic tenets into clinically useful therapeutic strategies. 
www.intechopen.com
 
Advances in the Biology, Imaging and Therapies for Glioblastoma 
 
58
7. References 
[1] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. Sep-Oct 
2010;60(5):277-300. 
[2] Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. Jul 31 2008;359(5):492-507. 
[3] Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy 
in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. Sep 
1978;49(3):333-343. 
[4] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and 
adjuvant temozolomide for glioblastoma. N Engl J Med. Mar 10 2005;352(10):987-996. 
[5] Alcantara Llaguno S, Chen J, Kwon CH, et al. Malignant astrocytomas originate from 
neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer 
Cell. Jan 6 2009;15(1):45-56. 
[6] Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human 
cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal 
markers in vitro. Glia. Sep 2002;39(3):193-206. 
[7] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the 
central nervous system. Acta Neuropathol. Aug 2007;114(2):97-109. 
[8] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. Jan 7 2000;100(1):57-70. 
[9] Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. Apr 9 
2009;458(7239):719-724. 
[10] TCGA. Comprehensive genomic characterization defines human glioblastoma genes 
and core pathways. Nature. Oct 23 2008;455(7216):1061-1068. 
[11] Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma 
predict prognosis, delineate a pattern of disease progression, and resemble stages 
in neurogenesis. Cancer Cell. Mar 2006;9(3):157-173. 
[12] Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies 
clinically relevant subtypes of glioblastoma characterized by abnormalities in 
PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. Jan 19 2010;17(1):98-110. 
[13] Brennan C, Momota H, Hambardzumyan D, et al. Glioblastoma subclasses can be 
defined by activity among signal transduction pathways and associated genomic 
alterations. PLoS One. 2009;4(11):e7752. 
[14] Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. Jul 5 
2002;297(5578):63-64. 
[15] Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. 
Mol Cell. Aug 1999;4(2):199-207. 
[16] Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability 
and tumorigenesis. Proc Natl Acad Sci U S A. Mar 30 1999;96(7):3940-3944. 
[17] Yokoyama K, Imamoto F. Transcriptional control of the endogenous MYC 
protooncogene by antisense RNA. Proc Natl Acad Sci U S A. Nov 1987;84(21):7363-
7367. 
[18] Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour 
maintenance. Nature. Jul 29 1999;400(6743):468-472. 
[19] Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. 
Oncogene. Dec 9 2002;21(56):8541-8546. 
[20] Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase 
cascade for the treatment of cancer. Oncogene. May 14 2007;26(22):3291-3310. 
www.intechopen.com
 
Key Principles in Glioblastoma Therapy 
 
59 
[21] Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer 
genomes. Nature. Mar 8 2007;446(7132):153-158. 
[22] Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted 
cancer therapy. Genes Dev. Dec 15 2007;21(24):3214-3231. 
[23] Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. 
Nat Rev Cancer. Sep 2005;5(9):689-698. 
[24] Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of 
glioblastomas to EGFR kinase inhibitors.[see comment][erratum appears in N Engl 
J Med. 2006 Feb 23;354(8):884]. New England Journal of Medicine. 2005;353(19):2012-
2024. 
[25] Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases 
affects the response of tumor cells to targeted therapies. Science. 2007;318(5848):287-
290. 
[26] Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-
oncogene addiction.[erratum appears in Cell. 2009 Aug 21;138(4):807]. Cell. 
2009;136(5):823-837. 
[27] Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple 
synthetic lethal interactions with the Ras oncogene. Cell. 2009;137(5):835-848. 
[28] Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human 
glioblastoma multiforme. Science. Sep 26 2008;321(5897):1807-1812. 
[29] Nitta M, Kozono D, Kennedy R, et al. Targeting EGFR induced oxidative stress by 
PARP1 inhibition in glioblastoma therapy. PLoS One. 2010;5(5):e10767. 
[30] Guo D, Hildebrandt IJ, Prins RM, et al. The AMPK agonist AICAR inhibits the growth 
of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci 
U S A. Aug 4 2009;106(31):12932-12937. 
[31] Guo D, Prins RM, Dang J, et al. EGFR signaling through an Akt-SREBP-1-dependent, 
rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci 
Signal. 2009;2(101):ra82. 
[32] Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by 
preferential activation of the DNA damage response. Nature. Dec 7 
2006;444(7120):756-760. 
[33] Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating 
cells. Nature. Nov 18 2004;432(7015):396-401. 
[34] Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of self-renewing tumor-
initiating cell types in glioblastoma. Cancer Cell. Apr 13 2010;17(4):362-375. 
[35] Sun Y, Kong W, Falk A, et al. CD133 (Prominin) negative human neural stem cells are 
clonogenic and tripotent. PLoS One. 2009;4(5):e5498. 
[36] Wang J, Sakariassen PO, Tsinkalovsky O, et al. CD133 negative glioma cells form 
tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. Feb 15 
2008;122(4):761-768. 
[37] Bao S, Wu Q, Li Z, et al. Targeting cancer stem cells through L1CAM suppresses glioma 
growth. Cancer Res. Aug 1 2008;68(15):6043-6048. 
[38] Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for 
tumor-initiating cells in human glioblastoma. Cell Stem Cell. May 8 2009;4(5):440-
452. 
www.intechopen.com
 
Advances in the Biology, Imaging and Therapies for Glioblastoma 
 
60
[39] Ogden AT, Waziri AE, Lochhead RA, et al. Identification of A2B5+CD133- tumor-
initiating cells in adult human gliomas. Neurosurgery. Feb 2008;62(2):505-514; 
discussion 514-505. 
[40] Lathia JD, Gallagher J, Heddleston JM, et al. Integrin alpha 6 regulates glioblastoma 
stem cells. Cell Stem Cell. May 7 2010;6(5):421-432. 
[41] Lee J, Son MJ, Woolard K, et al. Epigenetic-mediated dysfunction of the bone 
morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating 
cells. Cancer Cell. Jan 2008;13(1):69-80. 
[42] Ebben JD, Treisman DM, Zorniak M, Kutty RG, Clark PA, Kuo JS. The cancer stem cell 
paradigm: a new understanding of tumor development and treatment. Expert Opin 
Ther Targets. Jun 2010;14(6):621-632. 
[43] Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med. Jan 
2009;13(1):39-53. 
[44] Frank RT, Najbauer J, Aboody KS. Concise review: stem cells as an emerging platform 
for antibody therapy of cancer. Stem Cells. Nov 2010;28(11):2084-2087. 
www.intechopen.com
Advances in the Biology, Imaging and Therapies for Glioblastoma
Edited by Prof. Clark Chen
ISBN 978-953-307-284-5
Hard cover, 424 pages
Publisher InTech
Published online 09, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is intended for physicians and scientists with interest in glioblastoma biology, imaging and therapy.
Select topics in DNA repair are presented here to demonstrate novel paradigms as they relate to therapeutic
strategies. The book should serve as a supplementary text in courses and seminars as well as a general
reference.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Bartek Jiri Jr., Kimberly Ng, Bartek Jiri Sr., Santosh Kesari, Bob Carter and Clark C. Chen (2011). Key
Principles in Glioblastoma Therapy, Advances in the Biology, Imaging and Therapies for Glioblastoma, Prof.
Clark Chen (Ed.), ISBN: 978-953-307-284-5, InTech, Available from:
http://www.intechopen.com/books/advances-in-the-biology-imaging-and-therapies-for-glioblastoma/key-
principles-in-glioblastoma-therapy
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
